The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

doi:10.1158/1535-7163.MCT-13-0206

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Molecular cancer therapeutics - 1 Oct 2013

Anderson Ryan T, Keysar Stephen B, Bowles Daniel W, Glogowska Magdalena J, Astling David P, Morton J Jason, Le Phuong, Umpierrez Adrian, Eagles-Soukup Justin, Gan Gregory N, Vogler Brian W, Sehrt Daniel, Takimoto Sarah M, Aisner Dara L, Wilhelm Francois, Frederick Barbara A, Varella-Garcia Marileila, Tan Aik-Choon, Jimeno Antonio

Abstract excerpt

The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous cell carcinoma of the head and neck (HNSCC) has raised interest in exploring agents targeting PI3K, the product of PIK3CA. The genetic and molecular basis of rigosertib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Head and Neck Neoplasms

Share to Papillomaviridae

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Polo-Like Kinase 1

Share to Sulfones

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 23873848
DOI: 10.1158/1535-7163.MCT-13-0206
PMCID: PMC3796006

Genes

PLK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.PMID 23873848Read ↗

EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck CancersSemantic proximity Read ↗

Impact of PI3K pathway alterations on response to immune checkpoint inhibitors in HPV-negative head and neck squamous cell carcinomaSemantic proximity Read ↗

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)Semantic proximity Read ↗

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.Semantic proximity Read ↗

Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.Semantic proximity Read ↗

Exploring the antiproliferative effect of PI3K/Akt/mTOR pathway and CDK4/6 inhibitors in human papillomavirus‑positive and ‑negative head and neck squamous cell carcinoma cell linesSemantic proximity Read ↗

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerSemantic proximity Read ↗

Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines.Semantic proximity Read ↗

Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.Semantic proximity Read ↗

The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cellsSemantic proximity Read ↗

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Semantic proximity Read ↗

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.